WALTHAM, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of
high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive
Officer, will present at the Jefferies 2016 Healthcare Conference at 8:00 a.m. ET on Wednesday, June 8 in New York.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited
period of time following the conference event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of
high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major
life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating
Tangential Flow) systems and our growth factor products are used to increase product yield during the fermentation stage of
biologic drug manufacturing. In addition, we developed and market an innovative line of “ready-to-use” chromatography columns under
our OPUS® and MediaScout® brands that we deliver pre-packed with our customers’ choice of resin. Repligen’s corporate
headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten,
Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are
cautioned that statements in this press release which are not strictly historical statements including, without limitation,
statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions,
constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings
with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements,
except as required by law.
Contact: Sondra S. Newman Senior Director Investor Relations Repligen Corporation (781) 419-1881 snewman@repligen.com
